In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Seattle Genetics public offering nets $659mm to fund Cascadian purchase

Executive Summary

Seattle Genetics Inc. (targeted antibody-based cancer therapies) netted $659mm through a public offering of 13.27mm common shares (including the overallotment) at $52. Proceeds will fund the firm's acquisition of Cascadian Therapeutics; on the same day it announced the FOPO, Seattle Genetics offered $10 per share or approximately $614mm to purchase the oncology drug development company.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies